^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    An early phase study of ABT-199 in combination with tamoxifen in metastatic oestrogen receptor positive breast cancer

    Excerpt:
    ...a) ER positive (>1% positive stained carcinoma cells)...
    Trial ID:
    ACTRN12615000702516
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer

    Published date:
    12/05/2018
    Excerpt:
    In the first clinical study to evaluate venetoclax in a solid tumor, we demonstrate that combining venetoclax with endocrine therapy has a tolerable safety profile and elicits notable activity in ER and BCL2-positive metastatic breast cancer.
    Secondary therapy:
    tamoxifen
    DOI:
    10.1158/2159-8290.CD-18-1151